Back to top
more

Lineage Cell Therapeutics (LCTX)

(Delayed Data from AMEX)

$1.14 USD

1.14
313,327

+0.03 (2.70%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.13 -0.01 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lineage Cell Therapeutics, Inc. [LCTX]

Reports for Purchase

Showing records 21 - 40 ( 97 total )

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

02/22/2023

Daily Note

Pages: 8

Recent Approvals and New Agreements Support the Advancement of Current and Future Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

02/08/2023

Company Report

Pages: 4

BUY: Listen, You Should Hear This Story!

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

12/09/2022

Company Report

Pages: 4

BUY: Roche Kicks off a Phase 2a, multicenter, open-label, single-arm clinical study of OpRegen

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

11/28/2022

Company Report

Pages: 10

Global Partner Genentech Takes First Important Push Forward with OpRegen; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/21/2022

Company Report

Pages: 4

BUY: Can You See Route 66: Third Quarter Results

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/11/2022

Company Report

Pages: 10

3Q22 Results; Pending Regulatory Steps for OPC1 and VAC2; Preclinical Assets in the Making

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/04/2022

Company Report

Pages: 4

BUY: West Coast R&D & Expansion in Israel

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

08/19/2022

Company Report

Pages: 4

BUY: Reports 2nd QTR: Spending Lower $70M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

08/12/2022

Company Report

Pages: 10

2Q22 Results; We See OpRegen as Well Placed; Important Focus on Pipeline Now; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

06/02/2022

Company Report

Pages: 10

BD Track Record Continues to Build Future Potential Value; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

06/02/2022

Company Report

Pages: 4

Tune In to Our Recent Webinar with CEO-Brian Culley

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

05/13/2022

Company Report

Pages: 8

1Q22 Results; Cash Is King; Oh, and a Global Partnership, Data and Growing Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

05/03/2022

Company Report

Pages: 8

Fifth Retinal Restoration Disclosed At ARVO; Roche Certainly Happy With Its Investment

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

05/03/2022

Company Report

Pages: 4

BUY: The Data Continues to Build for OpRegen

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

04/25/2022

Daily Note

Pages: 8

Sights Set on Treating Vision Loss As Cell Therapy Pipeline Continues to Expand

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

04/13/2022

Daily Note

Pages: 7

Phase 1 Enrollment for VAC2 in NSCLC Checked; We Are Ready For Data in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

04/07/2022

Daily Note

Pages: 5

Views From the Summit - Preserving Vision From the Investing in Cures Summit 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

03/21/2022

Company Report

Pages: 8

Pipeline Expands As Long-Term Expertise Leveraged; Important Pattern Continues

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

03/11/2022

Company Report

Pages: 8

2021 Results; OPC1 Maturation Continues as FDA Discussions Near

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/11/2022

Company Report

Pages: 4

BUY: Ends the Year with $55M & Picks up Another $50M from Roche, That Ain’t Bad

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party